Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
MSFT 9.02META 26.5BKNG 9.7HMP.TO 0.01SPGP 1.21ZUQ.TO 1.52NVDA 7.26GL 0.63
Daily Stock Opinions and Ratings
The ultimate 360° Tracker Your financial life in one place, automatically
Stockchase Opinions

Michael SmedleyConjuChem IncCJB.TODON'T BUYApr 07, 2004

A very interesting company but has had a big run. Would look elsewhere.
Michael SmedleyMichael Smedley
Owned
Unlock Rating
$13.00

Stock price when the opinion was issued

biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
Get Signals Create your Watchlist

You might be interested:

DON'T BUY

ConjuChem Inc(CJB.TO)

Nov 26, 2007
Thinks it’s a horrible company. Last year they did $120 million of financing at $0.65. The $1 stock immediately plunged to $0.65. Last week they announced a $20 million financing at $0.15 convertible debenture. Has gone through $120 million in 12 months.
Photo of Peter HodsonPeter Hodson
No
Unlock Rating
$0.13

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

ConjuChem Inc(CJB.TO)

Apr 07, 2005
Thinks it will bounce around a little bit. Not his favourite name. Continue to spend a lot of money and ultimately will have to come back to the market, perhaps some time next year. With the state of biotechs, both large and small, it is not a sector he would want to be in right now. Doesn't like the management.
Photo of Peter HodsonPeter Hodson
No
Unlock Rating
$3.75

Stock price when the opinion was issued

biotechnologypharmaceutical
WEAK BUY

ConjuChem Inc(CJB.TO)

Feb 07, 2005
Had a problem with nausea on their drug. Data is improving. Starting to fix the nausea problem. A very effective product. Did another financing, so they are well cashed up. Not the best management team.
Photo of Peter HodsonPeter Hodson
No
Unlock Rating
$4.70

Stock price when the opinion was issued

biotechnologypharmaceutical
WAIT

ConjuChem Inc(CJB.TO)

Jan 06, 2005
Was concerned when their drug was causing nausea, so they sold. Thinks they will have to do a lot of work. Will watch to see if they can solve the problem.
Photo of Werner MuehelemannWerner Muehelemann
No
Unlock Rating
$4.91

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

ConjuChem Inc(CJB.TO)

Nov 04, 2004
The nausea under the diabetes drug is fixable under certain conditions, but the question is can the do it. If they can fix, it's a very robust product and will have a very big market.
Photo of Peter HodsonPeter Hodson
No
Unlock Rating
$3.49

Stock price when the opinion was issued

biotechnologypharmaceutical
WAIT

ConjuChem Inc(CJB.TO)

Sep 24, 2004
Sold his holdings because of the convertible debenture issued. Too early to go back in. Expect their will be a lot of tax selling towards the end of the year and will look at it at that time.
Photo of Peter HodsonPeter Hodson
No
Unlock Rating
$2.80

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

ConjuChem Inc(CJB.TO)

Sep 08, 2004
The drop out rate on their diabetes drug was higher than expected. Wasn't happy the way management disseminated the information. Dead money in the near term.
Photo of Andrew McCreathAndrew McCreath
No
Unlock Rating
$3.40

Stock price when the opinion was issued

biotechnologypharmaceutical
WEAK BUY

ConjuChem Inc(CJB.TO)

Aug 23, 2004
Feels there is a potential drug here. Probably is near its bottom. A fair risk/reward. They are trying a new formulation re: nausea of the drugs they tested in phase 2 trials. Also waiting for a combination trial.
Photo of Martin Hubbes, CFAMartin Hubbes, CFA
Owned
Unlock Rating
$3.99

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

ConjuChem Inc(CJB.TO)

Aug 06, 2004
Needs to know more before he would buy. Have to see better results in the future. Buy when it's rising.
Photo of Bruce Campbell (1)Bruce Campbell (1)
No
Unlock Rating
$3.61

Stock price when the opinion was issued

biotechnologypharmaceutical
TOP PICK

ConjuChem Inc(CJB.TO)

Jul 30, 2004
Not really happy with management. Took a big drop and is an interesting buy now. The drug works. Potential of being in phase three next year. Really cheap.
Photo of Ed HoEd Ho
Owned
Unlock Rating
$3.99

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

ConjuChem Inc(CJB.TO)

Jul 28, 2004
Not sure you should buy it at this time. You want to hold it when there is a possibility of approval being given for their product.
Photo of Michael SmedleyMichael Smedley
Owned
Unlock Rating
$4.27

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

ConjuChem Inc(CJB.TO)

Jul 15, 2004
A negative report on patient's reactions created a drop in the stock. Drugs in phase one or phase two trials can be very volatile. Prefers larger companies.
Photo of David DriscollDavid Driscoll
No
Unlock Rating
$4.80

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

ConjuChem Inc(CJB.TO)

Jul 08, 2004
An announcement is coming out next week and he thinks the news will be good, but would like it to be great. Speculative. Good management and balance sheet.
Photo of Peter HodsonPeter Hodson
Owned
Unlock Rating
$11.50

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

ConjuChem Inc(CJB.TO)

May 12, 2004
Stock has come off since they announced the successful trials on their diabetes applications. There is some risk, but has potential.
Photo of Michael SmedleyMichael Smedley
Owned
Unlock Rating
$11.72

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

ConjuChem Inc(CJB.TO)

Apr 22, 2004
Has had a huge move. Has moved too far, too fast. Solid programs. Expensive.
Photo of Glenn Paradis, BA, CFAGlenn Paradis, BA, CFA
No
Unlock Rating
$13.80

Stock price when the opinion was issued

biotechnologypharmaceutical

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

FCX 1.72$70.13
MU 106.38$1087.99
WDC 90.605$653.53
AAPL 5.29$296.42
SPCX 31.55$192.5

Today's Top Picks

MSFT 9.02$399.76
META 26.5$593.48
BKNG 9.7$174.64
HMP.TO 0.01$9.76
SPGP 1.21$121.6

Popular Articles

Latest Sell Signals

CRWD 10.11$692.91
MSFT 9.02$399.76
SCCO 3.43$193.22
ADBE 2.34$206.36
PEP 1.98$146.25

Most Recent Experts

Joe Terranova

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Gordon Reid

Gordon Reid

GoodReid Investment Counsel

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica